Phase I trial of metronomic oral topotecan in combination with pazopanib utilizing a daily dosing schedule to treat recurrent or persistent gynecologic tumors.
Todd D. Tillmanns
Research Funding - GlaxoSmithKline
Mark E. Reed
No relevant relationships to disclose
Melissa C. Privett
No relevant relationships to disclose
Amanda L. Johns
No relevant relationships to disclose
Mark S. Walker
No relevant relationships to disclose
Arthur C. Houts
No relevant relationships to disclose